FindTrial
Sign In

SCTV01E

BIOLOGICAL10 trials

Sponsors

Sinocelltech Ltd.

Conditions

COVID-19COVID-19 PandemicCOVID-19 SARS-CoV-2 InfectionSARS-CoV-2 InfectionSars-CoV-2 Infection

Phase 2

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
NCT05238441
Sinocelltech Ltd.COVID-19, Sars-CoV-2 Infection
Start: 2022-03-20End: 2023-05-01Target: 360Updated: 2022-03-02
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
NCT05239806
Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection
Start: 2022-04-01End: 2023-08-01Target: 400Updated: 2022-04-11
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
WithdrawnNCT05308602
Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection
Start: 2022-04-01End: 2023-08-01Updated: 2024-02-09
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
NCT05329051
Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection
Start: 2022-07-01End: 2023-03-01Target: 400Updated: 2022-04-14
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
NCT05345873
Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection
Start: 2022-07-01End: 2023-04-01Target: 300Updated: 2022-04-26
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
CompletedNCT05652543
Sinocelltech Ltd.COVID-19 Pandemic
Start: 2023-01-05End: 2024-01-15Updated: 2024-02-08
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
NCT05933512
Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection
Start: 2023-08-10End: 2024-11-10Target: 600Updated: 2023-07-06

Phase 3

A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years
Active, not recruitingNCT05308576
Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection
Start: 2022-12-26End: 2024-04-30Target: 10000Updated: 2024-04-15
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
NCT05323461
Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection
Start: 2022-05-30End: 2023-05-01Target: 1800Updated: 2023-04-10
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People
NCT05683561
Sinocelltech Ltd.COVID-19 SARS-CoV-2 Infection
Start: 2023-01-25End: 2024-08-25Target: 6000Updated: 2023-01-13

Related Papers

Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial
Vaccines2025-09-19
Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
Vaccines2025-01-07
Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial
Nature Communications2024-07-245 citations
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial
Vaccines2024-02-083 citations
Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial.
2023-09-0820 citations
Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men.
2023-07-0815 citations
A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants
Science China Life Sciences2022-12-3029 citations
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.
2022-12-0525 citations